Document Classification

Section Type: RESULTS

Text: Adverse events that occurred in at least 10 % of patients in either teriflunomide group and with an incidence that was at least 2 % higher than that with placebo were increased alanine aminotransferase (40 [19 %] of 216 patients in the 14 mg group, 36 [17 %] of 207 in the 7 mg group vs 27 [14 %] of 191 in the placebo group), hair thinning (25 [12 %] and 12 [6 %] vs 15 [8 %]), diarrhoea (23 [11 %] and 28 [14 %] vs 12 [6 %]), paraesthesia (22 [10 %] and 11 [5 %] vs 10 [5 %]), and upper respiratory tract infection (20 [9 %] and 23 [11 %] vs 14 [7 %]).